BioCryst has scrapped its already delayed hepatitis C treatment.
Company executives had hoped that BCX5191 would fare better in
chimpanzees than it had in a rat trial, but, according to a securities document filed Monday, that wasn’t the case.
The pressure was high for the drug to work, particularly since it’s
one of three candidates BioCryst has prioritized in a restructuring